A Contract Development and Manufacturing Organization handles drug development and production for other pharma or biotech companies. The work spans process development, scale-up, GMP manufacturing, fill-finish, packaging, and analytical testing.

Which European countries have the most CDMO capacity?

Switzerland and Germany lead by depth and quality (Basel, Heidelberg, Mainz). Poland adds large-scale manufacturing capacity, Lithuania has a growing biologics CDMO presence anchored in Vilnius, and the Nordics carry strong fill-finish and aseptic operators in Denmark and Sweden.

How are these CDMO companies verified?

Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory matrix (GMP / ISO-13485 / GLP / FDA-Inspected) backed by certification documents, and a registry note explaining the company's current operating context.

Can I compare two CDMO providers side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

Category page

CDMO companies in Europe — biotech directory

A CDMO (Contract Development and Manufacturing Organization) takes drug substance, drug product, or biologics work from another company through process development, scale-up, and GMP manufacturing. This directory lists verified European CDMO providers — biopharma manufacturers, fill-finish operators, API synthesis houses, and integrated contract manufacturing platforms — with hand-reviewed profiles, source-backed leadership, and compliance certifications.

Evidence

Visible records24

Verified24

Countries covered9

Regulated sites22

Avg sources / record0.0

Category view

Where does this category cluster most clearly?

CDMO is currently most visible through Finland (5), Germany (4), Latvia (3), and Estonia (2). Top cities: Olaine, Latvia (2), Oulu, Finland (2), Tartu, Estonia (2), and Vilnius, Lithuania (2). Most legible records: Pharmatory, Paras Biopharmaceuticals Finland, Bioglan, and AGC Biologics Denmark.

Category view

Which standards and public evidence are already visible?

GMP (21), GLP (1), ISO-13485 (2), and FDA-Inspected (3). Latest review: 22 March 2026. Review cycle: March 2026.

Category view

Why this category matters

This page brings companies and infrastructure records into one practical category view so users can compare markets and cities more quickly.

Category view

Related market brief

Where to look for biologics, fill-finish, small-molecule, and specialised CDMO capacity across Europe in 2026 — 33 CDMOs in the directory across 9 countries, organised by what they actually do and where they sit.

Open related brief

By country

CDMO by country

Jump into a country-specific page filtered to this category only.

Finland (5)Germany (4)Latvia (3)

Ranked list

Best CDMO Companies in Europe (2026)

Europe’s leading contract development and manufacturing organizations (CDMOs) — the partners biotech and pharma companies outsource drug-substance and drug-product manufacturing to. This ranking covers biologics, fill-finish, API synthesis, and viral-vector specialists across the Baltics, DACH, Poland, and the Nordics.

See the ranking

Explore more

Other categories

Therapeutics Manufacturing Diagnostics Infrastructure anchor Research CRO Tools Genomics Drug discovery Cluster

Full list

CDMO records

24 category records currently match the active filter.

Oulu API CDMO providing process R&D, analytical services, and cGMP contract manufacturing for human and veterinary pharmaceutical clients.

Lead: Jaana KarjalainenCEO and Managing Director
Scale: Commercial and development-stage API platform

Oulu biopharmaceutical company focused on biosimilars, recombinant biologics, and process technologies from a Finnish operating base.

Lead: Ashesh KumarFounder and Director
Scale: Development-stage biologics platform

Malmo CDMO and pharmaceutical manufacturer specializing in semi-solids, liquids, clinical-trial materials, and medtech-adjacent formulations from a Swedish GMP facility.

Lead: Simon BjorklundCEO
Scale: Commercial and clinical manufacturing platform

Soeborg biologics CDMO operation supporting clinical and commercial biopharmaceutical development and manufacturing from greater Copenhagen.

Lead: Alberto SantagostinoCEO
Scale: Commercial CDMO manufacturing platform

Hillerod biologics manufacturing site and CDMO platform within FUJIFILM Diosynth Biotechnologies, serving commercial and clinical biopharmaceutical production programs.

Lead: Martin MeesonCEO
Scale: Large-scale CDMO manufacturing platform

Kuopio gene-therapy CDMO and viral-products manufacturer operating cGMP production, drug-substance and drug-product suites, and a growing pharma campus in Savilahti.

Lead: Matthias KriegerManaging Director
Scale: Clinical-to-commercial gene-therapy manufacturing

Turku biologics and viral-vector CDMO site offering microbial proteins, plasmid DNA, viral vectors, aseptic fill-finish, and QC services under EMA-certified and FDA-inspected GMP operations.

Lead: Damaso MoleroChief Executive Officer
Scale: Investigational to commercial GMP manufacturing

Berlin biologics-development and bioanalytical platform supporting cell-line development, CMC, and analytical packages for biopharma programmes.

Lead: Philippe UlsemerCo-Founder and Chief Executive Officer
Scale: Integrated biologics-development platform

Tartu antibody-discovery and recombinant-protein platform now reinforced by a 1,600 m2 cGMP production facility and a broad partner network.

Lead: Mart UstavFounder and CEO
Scale: Clinical CDMO and cGMP protein manufacturing

Laupheim biologics CDMO anchor focused on mammalian production, late-stage development, and regulated commercial manufacturing.

Lead: Prof. Dr. Uwe BüchelerInterim Chief Executive Officer
Scale: Clinical-to-commercial CDMO manufacturing

Zofingen-led Swiss CDMO and API network operating a large regulated manufacturing footprint across drug substances and finished dosage.

Lead: Marcel ImwinkelriedChief Executive Officer
Scale: Global CDMO manufacturing

Stockholm-headquartered CDMO network spanning sterile, oral, and advanced pharmaceutical manufacturing across Europe.

Lead: Greg BeharChief Executive Officer
Scale: International CDMO manufacturing

Ravensburg aseptic-fill and injectable CDMO anchor operating one of Europe's most important sterile manufacturing networks.

Lead: Henryk Badack, Titus Ottinger, and Carsten PressManaging Directors
Scale: Global injectable CDMO manufacturing

Tartu API CDMO providing process chemistry, analytical development, scale-up, and GMP-oriented manufacturing support for small-molecule pharmaceutical programs.

Lead: Dr. Andrus TasaChairman of the Management Board
Scale: Clinical CDMO

Vilnius CDMO campus retained in the registry as the historical Biotechpharma operating base within Northway's current biologics manufacturing network.

Lead: Vladas Algirdas BumelisCEO, Executive Chairman of the Board and Advisory Board
Scale: Commercial CDMO

Helsinki particle-engineering CDMO using proprietary nanoforming technology to improve drug solubility and move small-molecule programs from development into clinical and commercial supply.

Lead: Edward HaeggstromChief Executive Officer
Scale: Clinical to Commercial

Olaine sterile fill-finish and lyophilization manufacturer supporting injectable drug production and contract development/manufacturing programs.

Lead: Vitalijs SkrivelisChief Executive Officer and Member of the Board
Scale: Commercial Pilot

German CDMO platform for viral vaccines, cell and gene therapy, and aseptic fill-finish manufacturing in Dessau-Rosslau. The verified March 2026 record ties the facility to current official executive leadership and live biologics production infrastructure.

Lead: Dr. Sally ChoeCo-CEO
Scale: Commercial biologics CDMO

Swiss commercial biologics and advanced-manufacturing titan spanning mammalian, microbial, and drug-product supply for global biopharma clients.

Lead: Renzo CicilliniSite Head Visp
Scale: Global commercial CDMO

Recombinant protein manufacturing node with Novavax-linked CDMO execution and GMP-compliant biologics infrastructure in Łódź. The verified March 2026 record captures Mabion's commercial biologics posture and end-to-end CDMO positioning.

Lead: Gregor KawaletzChief Executive Officer and President of the Management Board
Scale: Commercial biologics CDMO

Commercial biosimilars and mammalian cell culture platform spanning Gdansk and Warsaw under the Rezon Bio brand. Current registry record tracks the renamed Polish biologics CDMO layer through its March 2026 executive and operating surface.

Lead: Adriana Kiedzierska-MencfeldChief Executive Officer
Scale: Commercial biologics CDMO

Riga pharmaceutical manufacturing campus running API synthesis, finished-dose production, and quality-control workflows from Grindeks' long-standing Krustpils Street base.

Lead: Jānis RomanovskisChairman of the Board and CEO
Scale: Commercial / Industrial

Vilnius biologics CDMO anchor combining mammalian and microbial process development, GMP manufacturing, and BIO CITY expansion capacity inside Lithuania's main biopharma cluster.

Lead: Vladas Algirdas BumelisCEO and Chairman of the Board
Scale: Commercial CDMO

Olaine pharmaceutical manufacturing platform operating under the Olpha brand with commercial-scale synthesis, finished formulation, and Latvian GMP-backed production.

Lead: Juris Hme??ickisChairman of the Management Board and CEO
Scale: Commercial Scale

FAQ

Frequently asked questions

What is a CDMO?: A Contract Development and Manufacturing Organization handles drug development and production for other pharma or biotech companies. The work spans process development, scale-up, GMP manufacturing, fill-finish, packaging, and analytical testing.
Which European countries have the most CDMO capacity?: Switzerland and Germany lead by depth and quality (Basel, Heidelberg, Mainz). Poland adds large-scale manufacturing capacity, Lithuania has a growing biologics CDMO presence anchored in Vilnius, and the Nordics carry strong fill-finish and aseptic operators in Denmark and Sweden.
How are these CDMO companies verified?: Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory matrix (GMP / ISO-13485 / GLP / FDA-Inspected) backed by certification documents, and a registry note explaining the company's current operating context.
Can I compare two CDMO providers side by side?: Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

Next step

Read the category, then move into cities and countries.

Use city pages for local concentration, country pages for market context, and the methodology page when you want to understand how records are reviewed.

Open methodology Suggest a company

CDMO companies in Europe — biotech directory

Where does this category cluster most clearly?

Which standards and public evidence are already visible?

Why this category matters

Related market brief

CDMO by country

Best CDMO Companies in Europe (2026)

Other categories

CDMO records

Pharmatory

Paras Biopharmaceuticals Finland

Bioglan

AGC Biologics Denmark

FUJIFILM Diosynth Biotechnologies Denmark

FinVector

3PBIOVIAN

FyoniBio

Icosagen Group

Rentschler Biopharma

Siegfried

Recipharm

Vetter Pharma

TBD Pharmatech

Biotechpharma (Northway)

Nanoform Finland

PharmIdea

IDT Biologika

Lonza

Mabion S.A.

Rezon Bio

AS Grindeks

Northway Biotech

Olpha (formerly JSC Olainfarm)

Frequently asked questions

Read the category, then move into cities and countries.